Platelet Rich Plasma Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Platelet Rich Plasma Market is Segmented by Type (Pure PRP, Leukocyte-rich PRP, Leukocyte-rich Fibrin, and Other Types), Application (Orthopedics, Cosmetic Surgery and Dermatology, Neurology, Cardiology, Ophthalmology, and Other Applications), End User (Hospitals and Clinics and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). This industry report provides value in (USD billion) for the above segments.

Platelet Rich Plasma Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Platelet-Rich Plasma (PRP) Market Size

Platelet Rich Plasma Market Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 0.73 Billion
Market Size (2030) USD 1.30 Billion
CAGR (2025 - 2030) 12.18 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Platelet-Rich Plasma Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Platelet Rich Plasma Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Platelet-Rich Plasma (PRP) Market Analysis

The Global Platelet Rich Plasma Market size is estimated at USD 0.73 billion in 2025, and is expected to reach USD 1.30 billion by 2030, at a CAGR of 12.18% during the forecast period (2025-2030).

The key factors augmenting the platelet-rich plasma (PRP) market growth include the rising incidence of sports injuries, increasing cosmetic and surgical procedures, and the growing use of platelet-rich plasma in various therapeutic areas. The increasing burden of chronic diseases such as cardiovascular diseases among the population raises the demand for treatment through surgical intervention involving the use of PRP therapy. For instance, the use of platelet rich plasma (PRP) decreases the incidence and costs of wound complications and wound healing following cardiac and general surgery. Hence, the market growth of platelet rich plasma is anticipated to augment over the forecast period. For instance, as per the data from the Centers for Disease Control and Prevention (CDC) updated in May 2023, it was found that around 805,000 people in the United States have a heart attack every year. The growing number of heart attacks is leading to many surgical procedures, such as angioplasty, which is likely to augment the market growth. Additionally, as per the World Health Organization 2023 reports, the incidences of traumatic injuries, cancers, and cardiovascular disease continue to rise, and the impact of surgical intervention on public health systems will continue to grow globally, which is expected to enhance the demand of advanced PRP therapies around the globe.


The emergence of advanced PRP treatments and their utilization in various therapeutic fields have also helped the PRP market expand significantly. For instance, in December 2023, Hairline International Hair and Skin Clinic launched an advanced hair regeneration therapy called Sonicated PRP for hair loss, based on groundbreaking research utilizing platelet-rich plasma (PRP). The cutting-edge treatment aims to revolutionize hair follicle activation and regeneration. Similarly, in June 2023, Isto Biologics, a leader in orthobiologic regeneration technologies, launched Precise, a brand-new, state-of-the-art technology that delivers a final PRP product with precision cellular fractions upon concentration. Hence, owing to such advancements and PRP treatment, the launch of PRP therapies is expected to support the market growth positively and increase its adoption in various medical fields.


However, industry analysis shows that PRP treatments can be costly, especially in cases where multiple sessions are required. The expenses associated with the procedure — such as blood collection, processing, and preparation of the plasma — limit accessibility for some patients. In addition, the regulatory environment surrounding PRP treatments is unclear in many countries, making it difficult for medical practitioners to understand the legal framework which is likely to restraint the market growth.

Platelet Rich Plasma Industry Overview

The platelet-rich plasma market is highly competitive, with several players involved in the production of PRP products. The global market includes a mix of established medical device companies, specialized biotech firms, and regional players that offer a variety of PRP products targeting different medical fields such as orthopedic surgery, dermatology, aesthetics, and sports medicine.


Some of the key players currently dominating the market are Arthrex Inc., Isto Biologics, Vertical Spine LLC, DePuy Synthes, Dr. PRP USA LLC, EmCyte Corporation, Glofinn Oy, T-Biotechnology, Terumo BCT Inc., Zimmer Biomet, Harvest Technologies Corporation, ISTO Biologics. Companies focus on launching new products and getting approvals, which is likely to increase the availability of the products in the market.


For instance, in June 2023, Isto Biologics introduced Precise, the latest breakthrough in autologous therapies. Precise is an innovative and advanced technology that produces a highly concentrated platelet-rich plasma product with precise cellular fractions. The CellectFlex Technology of the Precise system enables customization of cell compositions during each spin, resulting in a unique range of offerings that were previously unavailable.


In addition, various players employ strategies like product innovation, geographic expansion, and M&A to maintain or grow their market share.

Platelet-Rich Plasma (PRP) Market Leaders

  1. EmCyte Corporation

  2. Zimmer Biomet

  3. Johnson & Johnson (DePuy Synthes)

  4. Arthrex Inc.

  5. Terumo BCT Inc

  6. *Disclaimer: Major Players sorted in no particular order
Platelet Rich Plasma Market Competitive Landscape
Need More Details on Market Players and Competiters?
Download PDF

Platelet-Rich Plasma (PRP) Market News

  • September 2024: the United States FDA cleared the FG-001 Platelet Rich Plasma (PRP) Device which is designed to be used for the safe and rapid preparation of platelet rich plasma (PRP) from a small sample of blood at the patient’s point of care.
  • August 2024: the United States FDA approved Illuminate PRP, designed for the swift and safe preparation of autologous platelet-rich plasma (PRP) from a minor peripheral blood sample, directly at the patient's point-of-care.
  • April 2024: The United States FDA has approved the Thrombinator System for use with Arthrex PRP Systems. These include the Arthrex Angel concentrated Platelet Rich Plasma (cPRP) System, the Arthrex Double Syringe (ACP) System, and the Arthrex ACP Max Platelet-Rich Plasma (PRP) System. The Thrombinator System is engineered to prepare autologous serum from both anticoagulated and non-anticoagulated peripheral blood. It can also process platelet-poor plasma and platelet-rich plasma (PRP). This prepared serum is intended to be mixed with PRP and either autograft or allograft bone before being applied to a bony defect, enhancing the handling characteristics of the mixture.
  • January 2024: Arthrex Demonstrated to the media the use of the ACP Max system for creating a highly concentrated platelet-rich plasma (PRP) with low neutrophil content.

Platelet-Rich Plasma (PRP) Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Sports Injuries
    • 4.2.2 Increasing Number of Cosmetic and Surgical Procedures
    • 4.2.3 Growing Use of Platelet Rich Plasma in Various Therapeutic Areas
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Policies
    • 4.3.2 High Prices of Plasma Therapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD billion)

  • 5.1 By Type
    • 5.1.1 Pure PRP
    • 5.1.2 Leukocyte-Rich PRP
    • 5.1.3 Leukocyte-Rich Fibrin
    • 5.1.4 Other Types
  • 5.2 By Application
    • 5.2.1 Orthopedics
    • 5.2.2 Cosmetic Surgery and Dermatology
    • 5.2.3 Neurology
    • 5.2.4 Cardiology
    • 5.2.5 Ophthalmology
    • 5.2.6 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals & Clinics
    • 5.3.2 Research Institutes
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arthrex Inc.
    • 6.1.2 Isto Biologics
    • 6.1.3 Vertical Spine LLC
    • 6.1.4 DePuy Synthes
    • 6.1.5 Dr. PRP USA LLC
    • 6.1.6 EmCyte Corporation
    • 6.1.7 Glofinn Oy
    • 6.1.8 T-Biotechnology
    • 6.1.9 Terumo BCT Inc.
    • 6.1.10 Zimmer Biomet
    • 6.1.11 Harvest Technologies Corporation
    • 6.1.12 ISTO Biologics
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Platelet-Rich Plasma (PRP) Industry Segmentation

As per the report's scope, platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels (which contains at least seven growth factors). Platelet-rich plasma therapy employs injections of the patient's concentrated platelets to accelerate the healing of injured tendons, ligaments, muscles, and joints.


The platelet rich plasma market segmentation includes type, application, end user, and geography. By type, the market is segmented into pure PRP, leukocyte-rich PRP, leukocyte-rich fibrin, and other types. By application, the market is segmented into orthopedics, cosmetic surgery and dermatology, neurology, cardiology, ophthalmology, and other applications. By end user, the market is segmented into hospitals and clinics, and research institutes. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market value (in USD billion) for the above segments. By Type Pure PRP   Leukocyte-Rich PRP Leukocyte-Rich Fibrin Other Types By Application Orthopedics   Cosmetic Surgery and Dermatology Neurology Cardiology Ophthalmology Other Applications By End User Hospitals & Clinics   Research Institutes   By Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America

By Type Pure PRP
Leukocyte-Rich PRP
Leukocyte-Rich Fibrin
Other Types
By Application Orthopedics
Cosmetic Surgery and Dermatology
Neurology
Cardiology
Ophthalmology
Other Applications
By End User Hospitals & Clinics
Research Institutes
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Platelet-Rich Plasma (PRP) Market Research FAQs

What are the main factors driving the growth of PRP ?

The key factors driving the market's growth include the rising incidence of sports injuries, increasing cosmetic and surgical procedures, and the growing use of platelet-rich plasma in various therapeutic areas.

Who are the major players in the PRP market?

EmCyte Corporation, Zimmer Biomet, Johnson & Johnson (DePuy Synthes), Arthrex Inc. and Terumo BCT Inc. are the major players operating in the platelet rich plasma market.

What are the current and emerging trends in PRP ?

Current and emerging trends in the PRP market include the increasing use of PRP for non-invasive aesthetic treatments like hair restoration and facial rejuvenation, growing adoption in orthopedic and regenerative medicine, advancements in PRP preparation technologies, and expanding market access in emerging regions like Asia-Pacific.

How much is the blood plasma market worth?

Blood plasma market was valued at USD 0.73 Billion in 2025 and is projected to reach USD 1.30 Billion by 2030, growing at a CAGR of 12.18% from 2025 to 2030.